Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.59 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL11374227 | 0.98 | MTNR1A (0.57) | MTNR1AMTNR1BMEN1KMT2ACYP3A4 | |
| SCHEMBL7434935 | 0.89 | SMN1; SMN2 (0.59) | MTNR1AMTNR1BHPGDSMN1; SMN2MAPT | |
| SCHEMBL28362501 | 0.86 | L3MBTL1 (0.60) | MTNR1AMTNR1BCYP3A4HPGDSMN1; SMN2 | |
| SCHEMBL7043060 | 0.84 | ALDH1A1 (0.62) | MEN1KMT2ACYP3A4HPGDSMN1; SMN2 | |
| SCHEMBL11216066 | 0.83 | MEN1 (0.62) | MEN1KMT2ACYP3A4HPGDSMN1; SMN2 | |
| SCHEMBL7436867 | 0.82 | HSD17B3 (0.52) | MEN1KMT2ACYP3A4MAPTKDM4E | |
| SCHEMBL7444387 | 0.82 | RAB9A (0.55) | MEN1KMT2ACYP3A4SMN1; SMN2MAPT | |
| SCHEMBL3231208 | 0.81 | ALDH1A1 (0.68) | MEN1KMT2ACYP3A4HPGDSMN1; SMN2 | |
| SCHEMBL3786992 | 0.80 | GSK3B (0.53) | MEN1KMT2ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL7440297 | 0.80 | KMT2A (0.54) | MEN1KMT2ACYP3A4HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594606-A | Asymmetric synthesis method of threo-2-hydroxy-3-acetamido-4-phenylcarbonyl butyric acid | 成都傲科新技术有限责任公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-113801006-B | Actetrophenone A compound and preparation and application thereof | 烟台水禾土生物科技有限公司 | 2022-07-12 | — | — | CN | claimed |
| WO-2007042114-A1 | PROCESS FOR THE OXIDATION OF ORGANIC SUBSTRATES BY MEANS OF SINGLET OXYGEN AT HIGH REACTION TEMPERATURES | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-04-19 | — | — | WO | claimed |
| WO-2007039034-A1 | PROCESS FOR PREPARING N-ACETYLAMINOACETOPHENONES AND DOWNSTREAM PRODUCTS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-04-12 | — | — | WO | claimed |
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025125561-A1 | THIOESTER PHOTOINITIATORS | ARKEMA FRANCE (FR) | 2025-06-19 | — | — | WO | disclosed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | CELLGENTEK CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| CN-115594606-A | Asymmetric synthesis method of threo-2-hydroxy-3-acetamido-4-phenylcarbonyl butyric acid | 成都傲科新技术有限责任公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115594606-A | Asymmetric synthesis method of threo-2-hydroxy-3-acetamido-4-phenylcarbonyl butyric acid | 成都傲科新技术有限责任公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-113173859-B | Method for synthesizing chiral alpha-amino alcohol compound | 温州大学 | 2022-08-19 | — | — | CN | disclosed |
| EP-0087953-B1 | ANTIBACTERIAL 1-NORMON-2-YL-HETEROCYCLIC COMPOUNDS | BEECHAM GROUP PLC (GB) | 1988-04-27 | — | — | EP | disclosed |
| US-4453003-A | ENZYME INHIBITORS, ANTIINFLAMMATORY AGENTS | UMEZAWA HAMAO (JP) | 1984-06-05 | — | — | US | disclosed |
| EP-0087953-A2 | Antibacterial 1-normon-2-yl-heterocyclic compounds | BEECHAM GROUP PLC (GB) | 1983-09-07 | — | — | EP | disclosed |
| US-4391986-A | Process for producing threo-3-amino-2-hydroxybutanoyl-aminoacetic acids, as well as novel intermediates therefor and process for producing them | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1983-07-05 | — | — | US | disclosed |
| US-4379929-A | BACTERIOSTATS | ELI LILLY AND COMPANY (US) | 1983-04-12 | — | — | US | disclosed |
| US-4281180-A | Process for producing threo-3-amino-2-hydroxybutanoyl-aminoacetic acids, as well as novel intermediated therefor and process for producing them | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1981-07-28 | — | — | US | disclosed |
| US-4053469-A | BACTERICIDES | SHIONOGI & CO., LTD. (JA) | 1977-10-11 | — | — | US | disclosed |
| US-3987039-A | ANTIBACTERIAL | SHIONOGI & CO., LTD. (JA) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | MTNR1A 546/4885MTNR1B 1079/4885MEN1 789/4885 |
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | KNTC1, MED1, LEF1 | MTNR1A 3436/4885MTNR1B 2814/4885MEN1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.